OrbiMed Genesis GP LLC (CIK 1808744) reported 33 SEC Form 4 insider transactions across 11 companies over the past 18 months (most recent 2026-09-23). Recent activity: Buy ETRA (2.0M shares), Buy ETRA (1.1M shares), Buy ETRA (1.7M shares), Buy ETRA (333,333 shares), Buy ETRA (758,279 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 2.0M | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 1.1M | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 1.7M | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 333,333 | $5.0M |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 758,279 | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 1.0M | $15.0M |
| 2026-08-11 | Braveheart Bio, Inc. (BRVE) | Director | Buy | 9.1M | $0 |
| 2026-08-11 | Braveheart Bio, Inc. (BRVE) | Director | Buy | 1.7M | $30.0M |
| 2026-08-11 | Braveheart Bio, Inc. (BRVE) | Director | Buy | 273,333 | $4.9M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 46,776 | $2.1M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 1,477 | $66,465 |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 787,024 | $35.7M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 24,846 | $1.1M |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 9,086 | $409,052 |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 272,322 | $12.3M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 1.2M | $10.0M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 625,000 | $5.0M |
| 2026-04-23 | Prelude Therapeutics Inc (PRLD) | Director | Buy | 1.7M | $7.5M |
| 2026-04-23 | Prelude Therapeutics Inc (PRLD) | Director | Buy | 1.1M | $5.0M |
| 2026-04-09 | Adicet Bio, Inc. (ACET) | 10% Owner | Sell | 29,319 | $191,453 |
| 2026-04-09 | Adicet Bio, Inc. (ACET) | 10% Owner | Sell | 2,400 | $15,312 |
| 2026-04-09 | Adicet Bio, Inc. (ACET) | 10% Owner | Sell | 32,523 | $204,570 |
| 2026-04-09 | Adicet Bio, Inc. (ACET) | 10% Owner | Sell | 40,416 | $263,512 |
| 2025-12-18 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 140,057 | $2.5M |
| 2025-12-18 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 74,465 | $1.3M |
来源：SEC Form 4 申报文件 · 截至 2026-09-23